AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Prior to the 1920s in the US, the soybean was mainly a forage crop, a source of oil, meal (for feed) and industrial products, with very little used as food. However, it took on an important role after World War I. During the Great Depression, the drought-stricken (Dust Bowl) regions of the United States were able to use soy to regenerate their soil because of its nitrogen-fixing properties. Farms were increasing production to meet with government demands, and Henry Ford became a promoter of soybeans. In 1931, Ford hired chemists Robert Boyer and Frank Calvert to produce artificial silk. They succeeded in making a textile fiber of spun soy protein fibers, hardened or tanned in a formaldehyde bath, which was given the name Azlon. It never reached the commercial market. Soybean oil was used by Ford in paint for the automobiles, as well as a fluid for shock absorbers. During World War II, soybeans became important in both North America and Europe chiefly as substitutes for other protein foods and as a source of edible oil. During the war, the soybean was discovered as fertilizer due to nitrogen fixation by the United States Department of Agriculture. Prior to the 1970s, Asian-Americans and Seventh-Day Adventists were essentially the only users of soy foods in the United States.
absolute zero A theoretical condition concerning a system at the lowest limit of the thermodynamic temperature scale, or zero kelvins, at which the system does not emit or absorb energy (i.e. all atoms are at rest). By extrapolating the ideal gas law, the internationally agreed-upon value for absolute zero has been determined as −273.15 °C (−459.67 °F; 0.00 K).
Maureen Vevers. Chair of Governors, Askham Bryan College, York. For services to Further Education. Alexandra Ellen Vincent. Lately Chief Operating Officer, Arts and Humanities Research Council. For services to Research Funding. Suman Vohra. Vice Chair, Edinburgh Hindu Mandir and Cultural Centre. For services to the community in Edinburgh. Belinda Alison Voos. Lately Nurse Consultant in Paediatric Neurosurgery, Great Ormond Street Hospital for Children NHS Foundation Trust. For services to Paediatric Neurosurgical Nursing. Dorothy Helen Wagstaff. Founder, CASCAID. For services to Charity. David Walker. Chair of Trustees, Horizons Specialist Academy Trust. For services to Education. Susan Walker. Chief Commissioner, Girlguiding Scotland. For services to Young People. David Wallace. Senior Fleet Staff Engineer, Royal National Lifeboat Institution. For voluntary service to Maritime Safety. Lady (Julia Elizabeth) Walport (Dr. Julia Neild). Lately Trustee, The Amber Trust and Trustee, Ealing Youth Orchestra. For services to Young People and to Charity. Keith Norman Walton. Founder, Severnside Community Rail Partnership. For services to Urban Rail Transport in Bristol. John Ward. Chair, Charles and Elsie Sykes Trust. For services to Charity and to the community in Harrogate, North Yorkshire. Pamela Joan Ward. For services to the community in Whipsnade, Bedfordshire. William John Ward. For services to the community in the New Forest, Hampshire. Edward Charles Warner. Disability and Access Ambassador, Cabinet Office Disability Unit. For services to Disabled People.
Susan Weintraub is an American scientist. She is a professor at the University of Texas Health Science Center at San Antonio (UTHSCSA). She received a BS in chemistry from the University of Pennsylvania in 1967, MS in chemistry from Trinity University in 1970 and a PhD in biochemistry from UTHSCSA in 1979. She was the president of the American Society for Mass Spectrometry for the period of 2012-2014. In 2017 she was named a Fellow of the American Association for the Advancement of Science (AAAS), and Fellow of the American Society for Mass Spectrometry in 2025. She is an associate editor of the Journal of Proteome Research. Her research focuses on biomedical mass spectrometry where she used mass spectrometry in the early 1970s for quantitative analysis of brain neurochemicals. She has been director of the mass spectrometry core resource at UTHSCSA since 1979.
Sources: en.wikipedia.org
=== Journal articles and book chapters === Humphreys, Laud. (1970). "Impersonal sex in public places." Transaction, January, 1970: 10–25. Humphreys, Laud. (1971). "New styles in homosexual manliness." Transaction, March/April 1971: 38–46, 64–65. Humphreys, Laud. (1974). "Homosexual exchanges in public places." pp. 129–142 in L. Rainwater (ed.), Social problems and public policy: Deviance and liberty. Hawthorne, NY: Aldine. Humphreys, Laud. (1975). "Predicting the unpredictable: Some crime prospects for the decade." The Participant, Winter. Humphreys, Laud. (1978). "An interview with Evelyn Hooker." Alternative lifestyles: Changing patterns in marriage, family, & intimacy, Vol. 1, No. 2. Humphreys, Laud. (1979). "Being odd against all odds." pp. 238–242 in R. Fedarico (ed.), Sociology (2nd edition). Reading, MA: Addison-Wesley. Humphreys, Laud. (1979). "Exodus and identity: The emerging gay culture." pp. 134–147 in M. Levine (ed.), Gay men: The sociology of male homosexuality. New York: Harper and Row. Humphreys, Laud. (1980). "Homosexuality in perspective." Society 17(6): 84–86. Humphreys, Laud; Miller, Brian. (1980). "Keeping in touch: Maintaining contact with stigmatized subjects." pp. 212–223 in W. Shaffir, R. Stebbins, and A. Turowetz (eds.), Field Work Experience: Qualitative Approaches to Social Research. New York: St. Martin's Press. Miller, Brian; Humphreys, Laud. (1980). "Lifestyles and violence: Homosexual victims of assault and murder." Qualitative Sociology 3(3): 169–185. Goodwin, Glenn A; Humphreys, Laud. (1982).
The objective of an atomic bomb is to produce a device, according to Serber, "...in which energy is released by a fast neutron chain reaction in one or more of the materials known to show nuclear fission." According to Rhodes, "Untamped, a bomb core even as large as twice the critical mass would completely fission less than 1 percent of its nuclear material before it expanded enough to stop the chain reaction from proceeding. Tamper always increased efficiency: it reflected neutrons back into the core and its inertia...slowed the core's expansion and helped keep the core surface from blowing away." Rearrangement of the core material's subcritical components would need to proceed as fast as possible to ensure effective detonation. Additionally, a third basic component was necessary, "...an initiator—a Ra + Be source or, better, a Po + Be source, with the radium or polonium attached perhaps to one piece of the core and the beryllium to the other, to smash together and spray neutrons when the parts mated to start the chain reaction." However, any bomb would "necessitate locating, mining and processing hundreds of tons of uranium ore...", while U-235 separation or the production of Pu-239 would require additional industrial capacity.
At the end of six months however, his forces managed to open a breach in the walls using battering rams, and the Muslim command sought to surrender in exchange for their lives before the final assault, the Muslim general having in fact delivered himself and his family to Ferdinand. The rest of the population, however, did not accept surrender and continued to resist. With food supplies running low in the city, it was violently taken by storm, with many killed and 5000 Muslims taken captive. King Ferdinand entered the city on 9 July 1064. The city was then delivered to Sesnando Davides, who ruled it as Count of Coimbra until his death in 1091. The city would become an important settlement place for Mozarabs (Portuguese: moçárabes) arriving from Muslim lands to the south.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.